Global Diabetic Retinopathy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 - 2025

  • ID: 4394846
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Alimera Sciences, Inc
  • Bayer Pharma AG
  • Genentech USA, Inc.
  • Iridex Corporation
  • Lumenis
  • Other Notable Players
  • MORE
Diabetic Retinopathy Market Growth, Future Prospects and Competitive Analysis, 2017-2025, the global diabetic retinopathy market was valued at USD 8.4 Bn in 2017, and is expected to reach USD 13.1 Bn by 2025, expanding at a CAGR of 6.7% from 2017 - 2025.

Market Insights

Perpetual growth in the prevalence of diabetes in middle- and low-income countries and further anticipation of future rise indicates the growth in prevalence of diabetic related complications, and hence diabetic retinopathy. Diabetic retinopathy is among the key causes of legal blindness in working adult population. With overall prevalence of around 34% in the total diabetes population, the burden in form of direct and indirect management cost of diabetic retinopathy is humongous. Treatment for diabetic retinopathy is determined upon the severity of condition, where non-proliferative diabetic retinopathy is excuses from treatment.

Along with high prevalence of diabetes and hence diabetic retinopathy, wide availability of treatment options also serve as key drivers of this market. At present, diabetic retinopathy is mostly treated with laser treatment and vitrectomy. As the prevalence of macular edema in diabetic retinopathy is on rise, it is anticipated that the demand for treatment drugs and injections will steadily grow. Rise in healthcare expenditure is another key contributor to the growth of diabetic retinopathy market. However, the market growth may be shunted due to shortage of skilled professional for treating diabetes and related complications. The key diabetic retinopathy treatment drugs studied in this report are Aflibercept (Eylea), Bevacizumab (Avastin), Fluocinolone acetonide (Iluvien), Ranibizumab (Lucentis) and Triamcinolone acetonide.

Geographically, this report studies the diabetic retinopathy for North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America markets. These regions are further split into key country-level markets that determine the overall trends in respective regional market. Among the considered geographies, North America and Europe together take over 50% of the global market share for diabetic retinopathy treatments. High awareness, early introduction of breakthrough treatment devices and drugs, extensive research initiatives being taking place in the U.S. and Western Europe and favorable reimbursements are the key factors that contribute to the dominance of these regions.

Phenomenal rise in prevalence of diabetes in India, China and other middle- and low-income countries of Asia-Pacific and Middle East and Africa make these regions the fastest growing geographical markets during the forecast period. Other drivers of diabetic retinopathy market in Asia-Pacific and Middle East and Africa markets are rapid development of healthcare infrastructure, growing focus of market players to develop their foothold in Asia and Middle East markets, and growing government and non-government initiatives for developing awareness about diabetes management in the general population.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alimera Sciences, Inc
  • Bayer Pharma AG
  • Genentech USA, Inc.
  • Iridex Corporation
  • Lumenis
  • Other Notable Players
  • MORE
Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Diabetic Retinopathy Treatment Devices Market, by Type, 2015 (USD Mn)
2.2 Diabetic Retinopathy Treatment Drugs Market, by Type, 2015 (USD Mn)
2.3 Diabetic Retinopathy Market Share, by Geography, 2015 (Value %)

Chapter 3 Diabetic Retinopathy Market: Market Dynamics and Outlook
3.1 Introduction
3.2 Diabetic Retinopathy: Facts and Figures
3.3 Drivers
3.4 Challenges
3.5 Future Prospects
3.6 Attractive Investment Proposition
3.1 Competitive Analysis: Market Positioning, by Key Market Players

Chapter 4 Global Diabetic Retinopathy Treatment Devices Market Analysis, by Device Type, 2015 - 2025 (USD Mn)
4.1 Preface
4.2 Focal Laser Treatment
4.3 Scatter Laser Treatment
4.4 Vitrectomy Devices

Chapter 5 Global Diabetic Retinopathy Drugs Market Analysis, by Drug Type, 2015 - 2025 (USD Mn)
5.1 Preface
5.2 Aflibercept (Eylea)
5.3 Bevacizumab (Avastin)
5.4 Fluocinolone Acetonide (Iluvien)
5.5 Ranibizumab (Lucentis)
5.6 Triamcinolone Acetonide Injection

Chapter 6 Global Diabetic Retinopathy Market, by Geography, 2015 - 2025 (USD Mn)
6.1 Preface
6.2 North America
6.2.1 U.S.
6.2.2 Canada
6.3 Europe
6.3.1 U.K.
6.3.2 Germany
6.3.3 Rest of Europe
6.4 Asia-Pacific
6.4.1 Japan
6.4.2 China
6.4.3 Rest of Asia-Pacific
6.5 Middle East and Africa (MEA)
6.6 Latin America

Chapter 7 Company Profiles
7.1 Alimera Sciences, Inc
7.1.1 Business Description
7.1.2 Financial Health and Budget Allocation
7.1.3 Product Positions/Portfolio
7.1.4 News Coverage
7.2 Pfizer
7.2.1 Business Description
7.2.2 Financial Health and Budget Allocation
7.2.3 Product Positions/Portfolio
7.2.4 News Coverage
7.3 Genentech USA, Inc.
7.3.1 Business Description
7.3.2 Financial Health and Budget Allocation
7.3.3 Product Positions/Portfolio
7.3.4 News Coverage
7.4 Sandoz Inc.
7.4.1 Business Description
7.4.2 Financial Health and Budget Allocation
7.4.3 Product Positions/Portfolio
7.4.4 News Coverage
7.5 Bayer Pharma AG
7.5.1 Business Description
7.5.2 Financial Health and Budget Allocation
7.5.3 Product Positions/Portfolio
7.5.4 News Coverage
7.6 Regeneron Pharmaceuticals Inc.
7.6.1 Business Description
7.6.2 Financial Health and Budget Allocation
7.6.3 Product Positions/Portfolio
7.6.4 News Coverage
7.7 Sirnaomics
7.7.1 Business Description
7.7.2 Financial Health and Budget Allocation
7.7.3 Product Positions/Portfolio
7.7.4 News Coverage
7.8 Iridex Corporation
7.8.1 Business Description
7.8.2 Financial Health and Budget Allocation
7.8.3 Product Positions/Portfolio
7.8.4 News Coverage
7.9 Lumenis
7.9.1 Business Description
7.9.2 Financial Health and Budget Allocation
7.9.3 Product Positions/Portfolio
7.9.4 News Coverage
7.10 Valon Lasers OY
7.10.1 Business Description
7.10.2 Financial Health and Budget Allocation
7.10.3 Product Positions/Portfolio
7.10.4 News Coverage
7.11 Other Notable Players

List of Figures
Fig. 1 Diabetic Retinopathy: Market Segmentation
Fig. 2 Diabetic Retinopathy Treatment Devices, by Type, 2015 (USD Mn)
Fig. 3 Diabetic Retinopathy Treatment Drugs Market, Type, 2015 (USD Mn)
Fig. 4 Diabetic Retinopathy Market Share, by Geography, 2015 (Value %)
Fig. 5 Attractive Investment Proposition, Diabetic Retinopathy Market, 2015
Fig. 6 Competitive Analysis: Market Positioning, by Key Market Players
Fig. 7 Global Focal Laser Treatment Market, 2015 - 2025 (USD Mn)
Fig. 8 Global Scatter Laser Treatment Market, 2015 - 2025 (USD Mn)
Fig. 9 Global Vitrectomy Devices Market, 2015 - 2025 (USD Mn)
Fig. 10 Global Aflibercept (Eylea) Market, 2015 - 2025 (USD Mn)
Fig. 11 Global Bevacizumab (Avastin) Market, 2015 - 2025 (USD Mn)
Fig. 12 Global Fluocinolone Acetonide (Iluvien) Market, 2015 - 2025 (USD Mn)
Fig. 13 Global Ranibizumab (Lucentis) Market, 2015 - 2025 (USD Mn)
Fig. 14 Global Triamcinolone Acetonide Injection Market, 2015 - 2025 (USD Mn)
Fig. 15 U.S. Diabetic Retinopathy Market, 2015 - 2025 (USD Mn)
Fig. 16 U.K. Diabetic Retinopathy Market, 2015 - 2025 (USD Mn)
Fig. 17 Germany Diabetic Retinopathy Market, 2015 - 2025 (USD Mn)
Fig. 18 Rest of Diabetic Retinopathy Market, 2015 - 2025 (USD Mn)
Fig. 19 Japan Diabetic Retinopathy Market, 2015 - 2025 (USD Mn)
Fig. 20 China Diabetic Retinopathy Market, 2015 - 2025 (USD Mn)
Fig. 21 Rest of Asia-Pacific Diabetic Retinopathy Market, 2015 - 2025 (USD Mn)
Fig. 22 Middle East and Africa Diabetic Retinopathy Market, 2015 - 2025 (USD Mn)
Fig. 23 Latin America Diabetic Retinopathy Market, 2015 - 2025 (USD Mn)

List of Tables
Table 1 Global Diabetic Retinopathy Treatment Devices Market, by Device Type, 2015 - 2025 (USD Mn)
Table 2 Global Diabetic Retinopathy Drugs Market, by Drug Type, 2015 - 2025 (USD Mn)
Table 3 Global Diabetic Retinopathy Market, by Geography, 2015 - 2025 (USD Mn)
Table 4 North America Diabetic Retinopathy Market, by Country, 2015 - 2025 (USD Mn)
Table 5 Canada Diabetic Retinopathy Market, 2015 - 2025 (USD Mn)
Table 6 Europe Diabetic Retinopathy Market, by Country, 2015 - 2025 (USD Mn)
Table 7 Asia-Pacific Diabetic Retinopathy Market, by Country, 2015 - 2025 (USD Mn)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Alimera Sciences, Inc
  • Pfizer
  • Genentech USA, Inc.
  • Sandoz Inc.
  • Bayer Pharma AG
  • Regeneron Pharmaceuticals Inc.
  • Sirnaomics
  • Iridex Corporation
  • Lumenis
  • Valon Lasers OY
  • Other Notable Players
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll